| 35.42 -0.26 (-0.73%) | 03-17 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 44.18 | 1-year : | 47.24 |
| Resists | First : | 37.83 | Second : | 40.45 |
| Pivot price | 37.07 |
|||
| Supports | First : | 33.59 | Second : | 27.95 |
| MAs | MA(5) : | 35.3 |
MA(20) : | 37.32 |
| MA(100) : | 34.58 |
MA(250) : | 19.43 |
|
| MACD | MACD : | -0.7 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 20.9 |
D(3) : | 18.4 |
| RSI | RSI(14): 42.3 |
|||
| 52-week | High : | 43.72 | Low : | 3.72 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ COGT ] has closed above bottom band by 24.3%. Bollinger Bands are 28.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 36.09 - 36.29 | 36.29 - 36.45 |
| Low: | 34.38 - 34.67 | 34.67 - 34.9 |
| Close: | 35 - 35.42 | 35.42 - 35.77 |
Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. It has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Tue, 17 Mar 2026
COGT Shares Climb After FDA Accepts Bezuclastinib NDA for Non-Advanced SM - Bitget
Tue, 17 Mar 2026
COGT Rise as FDA Accepts Bezuclastinib NDA in Non-Advanced SM - TradingView
Tue, 17 Mar 2026
Cinctive Capital Management LP Buys Shares of 111,058 Cogent Biosciences, Inc. $COGT - MarketBeat
Tue, 17 Mar 2026
Boothbay Fund Management LLC Cuts Holdings in Cogent Biosciences, Inc. $COGT - MarketBeat
Mon, 16 Mar 2026
Raymond James Maintains Strong Buy for Cogent Biosciences (COGT) March 2026 - Meyka
Mon, 16 Mar 2026
Jefferies Initiates Buy Rating for Cogent Biosciences (COGT) wit - GuruFocus
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 162 (M) |
| Shares Float | 151 (M) |
| Held by Insiders | 0.3 (%) |
| Held by Institutions | 107.6 (%) |
| Shares Short | 16,280 (K) |
| Shares Short P.Month | 16,440 (K) |
| EPS | -2.17 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.4 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -33 % |
| Return on Equity (ttm) | -73.7 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -2.04 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -264 (M) |
| Levered Free Cash Flow | -152 (M) |
| PE Ratio | -16.4 |
| PEG Ratio | 0 |
| Price to Book value | 10.41 |
| Price to Sales | 0 |
| Price to Cash Flow | -21.75 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|